Xenon Pharmaceuticals (XENE) investors approve 2026 equity plan and pay votes
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Xenon Pharmaceuticals Inc. reported results of its annual meeting of shareholders held on June 2, 2026. Shareholders approved a new 2026 Equity Incentive Plan to replace the prior 2014 plan, following the Board of Directors’ recommendation.
Shareholder turnout was high, with 90,399,636.29 common shares, representing approximately 93.54% of shares entitled to vote, present or represented by proxy. All director nominees were elected, the advisory "say‑on‑pay" vote on executive compensation was approved, and shareholders supported holding this advisory vote every one year. Shareholders also approved the appointment of PricewaterhouseCoopers LLP as independent auditor and authorized the audit committee to set the auditor’s remuneration.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Shares represented at meeting: 90,399,636.29 shares
Say-on-pay votes for: 82,156,320.53 votes
Say-on-pay votes against: 4,769,025.65 votes
+5 more
8 metrics
Shares represented at meeting
90,399,636.29 shares
Common shares present or by proxy at annual meeting; 93.54% of eligible
Say-on-pay votes for
82,156,320.53 votes
Advisory approval of named executive officer compensation
Say-on-pay votes against
4,769,025.65 votes
Advisory vote on named executive officer compensation
Equity plan votes for
58,579,810.00 votes
Approval of 2026 Equity Incentive Plan
Equity plan votes against
27,570,443.18 votes
Approval of 2026 Equity Incentive Plan
1-year say-on-pay frequency votes
86,918,084.18 votes
Preference for annual advisory vote on executive compensation
Auditor reappointment votes for
90,371,967.64 votes
Appointment of PricewaterhouseCoopers LLP as auditor
Shares entitled to vote (implied baseline)
approx. 96,648,000 shares
Derived from 90,399,636.29 shares representing 93.54% entitled to vote
Key Terms
2026 Equity Incentive Plan, Say-on-Pay, Broker Non-Votes, emerging growth company, +1 more
5 terms
2026 Equity Incentive Plan financial
"approved the Xenon Pharmaceuticals Inc. 2026 Equity Incentive Plan (the “2026 Plan”), to replace the Amended and Restated Xenon Pharmaceuticals Inc. 2014 Equity Incentive Plan"
Say-on-Pay financial
"Proposal Two – Advisory Vote on Compensation of Named Executive Officers (“Say-on-Pay”)."
A say-on-pay is a shareholder vote that gives investors a chance to approve or disapprove a company’s executive compensation packages, typically held at annual meetings. It matters because the vote signals investor satisfaction with how leaders are paid—like customers rating how well managers are rewarded—and can push boards to change pay plans, reducing governance risk and affecting investor confidence and stock value even though the vote is usually advisory rather than legally binding.
Broker Non-Votes financial
"For | | | Against | | | Abstain | | | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
emerging growth company regulatory
"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
independent registered public accounting firm financial
"the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the ensuing year was approved"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
FAQ
How often will Xenon Pharmaceuticals hold future say-on-pay votes?
Shareholders favored holding say‑on‑pay votes every one year, with 86,918,084.18 votes for a one‑year frequency. Smaller vote totals supported two‑year, three‑year, or abstention options, while broker non‑votes totaled 3,407,133.11 on this frequency proposal.